- Home
- DHT vs HCM Comparison
DHT vs HCM Comparison
Compare DHT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHT | HCM |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | Bermuda | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.7B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | DHT | HCM |
|---|---|---|
| Price | $13.43 | $15.54 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $15.67 | $13.75 |
| AVG Volume (30 Days) | ★ 2.0M | 57.5K |
| Earning Date | 02-04-2026 | 08-07-2025 |
| Dividend Yield | ★ 7.09% | N/A |
| EPS Growth | ★ 23.62 | N/A |
| EPS | ★ 1.24 | 0.53 |
| Revenue | $538,571,000.00 | ★ $602,197,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $38.95 | $15.54 |
| P/E Ratio | $10.80 | ★ $5.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.00 | $11.51 |
| 52 Week High | $13.90 | $19.50 |
Technical Indicators
Market Signals| Indicator | DHT | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 62.71 |
| Support Level | $13.12 | $14.63 |
| Resistance Level | $13.90 | $16.33 |
| Average True Range (ATR) | 0.43 | 0.45 |
| MACD | 0.08 | 0.18 |
| Stochastic Oscillator | 78.32 | 73.48 |
Price Performance
Historical ComparisonAbout DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.